Own CSL shares? Here’s how the company actually makes money

What is the revenue generating machine of CSL Limited?

| More on:
smiling health care workers in a medical setting

Image source: Getty Images

As a long-term investor, it is incredibly important to see companies, such as CSL Limited (ASX: CSL), and its shares, as more than flickering ticker codes with an erratic dollar value. Instead, these listed entities are collections of people with a shared mission.

Part of what makes a company valuable is its mission and what it does to work towards that goal. That being said, it can be easy to lose sight of what a company does that provides shareholders with a return. Even for a company with the stature of CSL, Australia’s second-largest listed company by market capitalisation, understanding the money-making business activity can be lost in the pile of information.

For this reason, we’ll be diving into how CSL shares actually earn their keep in the present day.

How does CSL make money?

Although CSL isn’t quite a ‘household’ name, its products have touched the lives of many people. The company’s roots stem all the way from 1916 when it was known as Commonwealth Serum Laboratories, an Australian government-owned entity involved in vaccine manufacture.

While its history is extensive and incredibly interesting, spattered with a long list of monumental breakthroughs in modern medicine, we are here to cover how the CSL we know today makes money.

The publically-listed and privatised version of CSL that Aussies invest in these days has two distinct business operations. These two businesses include CSL Behring and Seqirus.

Firstly, CSL Behring is a provider of medicines to treat people with rare and serious diseases. These treatments are across multiple areas of immunology, haematology, cardiovascular, and transplant therapeutics. In terms of how much money the Behring business ‘Beh-rings’ in, it is more than 80% of the company’s US$10.3 billion of annual revenue. This is derived through the sale of its broad range of products including tetanus shots, coagulants, etc. to more than 100 countries.

Secondly, the Seqirus side of CSL’s operations is focused on influenza vaccines. In fact, Seqirus is one of the leading providers of ‘flu shots in the world. However, investors in CSL shares mightn’t know it manufactures a unique range of products made in the national interest. These products include antivenoms and Q fever vaccines.

In FY21, Seqirus pulled in total revenue of $1.736 billion, an increase of 30% year on year. This was due to the strong demand for CSL’s influenza vaccines to reduce strain on hospitals during COVID-19.

How have CSL shares performed?

The CSL share price has been a solid performer over long time periods. For example, in the last five years, the CSL share price has gained 208%. This represents a compound annual growth rate (CAGR) of 25.28%, which far outpaces the S&P/ASX 200 Index (ASX: XJO) CAGR of 7.22% in the last five years.

However, CSL returns have been more modest over the past 12 months. In the last year, the CSL share price has climbed 6.18% higher, significantly lower than its historical performance.

Should you invest $1,000 in CSL Limited right now?

Before you consider CSL Limited, you'll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and CSL Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of January 13th 2022

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Imugene (ASX:IMU) share price leaps 10% on new Roche deal

Key Points Imugene shares rocket on back of new supply agreement with Roche Clinical trial of PD1-Vaxx will be combined …

Read more »

Lab technician analyses a sample in a laboratory for a clinical trial
Healthcare Shares

Race Oncology (ASX:RAC) share price rises following preclinical discovery

Key points The Race Oncology share price is up as high as 2.8% today A new discovery relating to heart …

Read more »

shocked man with hands over his face with a declining graph in background representing falling CleanSpace share price
Healthcare Shares

Why the AnteoTech (ASX:ADO) share price is plummeting 23% on Friday

Key Points AnteoTech shares sink on additional request for information by the TGA The company submitted a performance report last …

Read more »

Group of Imugene scientists cheering in the lab after the company received another patent for HER-Vaxx
Healthcare Shares

Why the Imugene (ASX:IMU) share price advanced 5% on market open

Key points Imugene share price soared 5% on the back of European patent approval This is further intellectual protection for …

Read more »

A healthcare worker wearing a white coat holds his fingers to his mouth looking worried as healthcare stocks like Cochlear crash today
Earnings Results

ResMed (ASX:RMD) share price on watch after Q2 update disappoints

Key points ResMed delivered solid revenue and profit growth in the second quarter A major competitor product recall boosted demand …

Read more »

Lab worker puts hands in the air and dances around
Healthcare Shares

Here’s why the Rhythm Biosciences (ASX:RHY) share price soared 8% today

Key points The Rhythm Biosciences share price finished the day up by more than 8% after earlier jumping by 19% …

Read more »

gloved hand holding covid-19 vaccine against backdrop of australian flag
Healthcare Shares

Own CSL (ASX:CSL) shares? Here’s why the company is moving on from COVID research

CSL Limited (ASX: CSL) shares are joining the broader ASX selloff today, down 3.93% to $248.20 per share. The S&P/ASX …

Read more »

Graph showing a fall in share price.
Healthcare Shares

Why is the Cochlear (ASX:COH) share price tumbling 5% on Thursday?

Key points Cochlear is one of the worst performing ASX 200 healthcare stocks on Thursday Right now, its share price …

Read more »